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Kaposi’s sarcoma-associated herpesvirus (KSHV) is the etiological agent of primary effusion lymphoma (PEL), which
represents a rapidly progressing malignancy arising in HIV-infected patients. Conventional chemotherapy for PEL
treatment induces unwanted toxicity and is ineffective — PEL continues to portend nearly 100% mortality within a
period of months, which requires novel therapeutic strategies. The amino acid transporter, xCT, is essential for the
uptake of cystine required for intracellular glutathione (GSH) synthesis and for maintaining the intracellular redox
balance. Inhibition of xCT induces growth arrest in a variety of cancer cells, although its role in virus-associated
malignancies including PEL remains unclear. In the current study, we identify that xCT is expressed on the surface of
patient-derived KSHV+ PEL cells, and targeting xCT induces caspase-dependent cell apoptosis. Further experiments
demonstrate the underlying mechanisms including host and viral factors: reducing intracellular GSH while increasing
reactive oxygen species (ROS), repressing cell-proliferation-related signaling, and inducing viral lytic genes. Using an
immune-deficient xenograft model, we demonstrate that an xCT selective inhibitor, Sulfasalazine (SASP), prevents PEL
tumor progression in vivo. Together, our data provide innovative and mechanistic insights into the role of xCT in PEL
pathogenesis, and the framework for xCT-focused therapies for AIDS-related lymphoma in future.
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The oncogenic γ-herpesvirus known as the Kaposi’s
sarcoma-associated herpesvirus (KSHV) is a principal
causative agent of cancer arising in patients with compro-
mised immune systems [1]. One of these cancers, primary
effusion lymphoma (PEL), comprises transformed B cells
harboring KSHV episome and arises preferentially within
the pleural or peritoneal cavities of patients infected with
HIV [2]. PEL is a rapidly progressing malignancy with a
median survival time of approximately 6 months [3]. Cur-
rently, combinational chemotherapy is the standard of care
for PEL, and cyclophosphamide, doxorubicin, vincristine,* Correspondence: zqin@lsuhsc.edu
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unless otherwise stated.and prednisone (CHOP) regimens are considered first-line
therapy [4,5]. However, the myelosuppressive effects of sys-
temic cytotoxic chemotherapy synergize with those caused
by antiretroviral therapy or immune suppression [3,4,6].
Several novel approaches for PEL therapy have been re-
ported in recent studies and increase survival for some pa-
tients, but a lack of sufficient safety and efficacy data have
precluded their routine use. The proteasome inhibitor bor-
tezomib and the combination of arsenic trioxide and inter-
feron both suppress the NF-κB activation and may work
synergistically with cytotoxic chemotherapy to reduce PEL
viability [7,8]. Unfortunately, proteasome inhibition and
arsenic incur significant toxicities limiting their clinical ap-
plication. The mammalian target of rapamycin (mTOR) in-
hibitor, sirolimus inhibits PEL cell growth in a murine
xenograft model [7], but which paradoxically induces ex-
pression of the serine/threonine kinase Akt and tumor cell
growth, resulting in treatment failures [8]. Recently, we re-
port that inhibition of sphingosine kinase 2 (SphK2) by a
novel compound, ABC294640, effectively prevents and. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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novel targeted, safer and more effective strategies are ur-
gently needed for PEL treatment.
The xc
− antiporter, consisting of xCT (also named as
SLC7A11) and its chaperone CD98, functions as a
Na+-independent electroneutral exchange system for cyst-
ine/glutamate [10]. Expression of xCT on the cell mem-
brane is essential for the uptake of cystine required for
intracellular glutathione (GSH) synthesis, which plays an
important role in maintaining the intracellular redox bal-
ance [11,12]. Cystine/cysteine represents an essential
amino acid for many cancer cells and its uptake from the
microenvironment is crucial for their growth and viability.
Therefore, xCT is highly expressed by a variety of malig-
nant tumors [13-16], and also contributes to multidrug re-
sistance for cancer cells [17,18].
Interestingly, xCT has been also identified as a fusion-
entry receptor for KSHV and mediated KSHV entry
either in isolation or as part of a complex with other re-
ceptors for the virus [19,20]. Recently, our study has
demonstrated that xCT is upregulated within more
advanced Kaposi’s sarcoma (KS, another KSHV-caused
malignancy) lesions containing a greater number of
KSHV-infected cells [21]. Moreover, xCT can be upregu-
lated by KSHV-microRNAs by directly targeting BACH-1,
one of the negative transcription regulators of xCT,
thereby facilitating viral dissemination and persistence in
the host [21]. In the same study, we also report that xCT
protects KSHV-infected endothelial cells from death in-
duced by reactive oxygen species (ROS) [21]. In another
our recent study, we report that xCT is able to activate
intracellular signaling pathways especially MAPK, cyto-
kine release and cell invasiveness through induction of 14-
3-3β protein [22]. Even though these understandings
about xCT and KSHV pathogenesis, it remains unclear
whether xCT is also expressed on KSHV-infected PEL
tumor cells and its functions in PEL pathogenesis espe-
cially tumor cells growth/survival and underlying complex
mechanisms. More importantly, it is interested to know
whether targeting xCT may represent a promising thera-
peutic strategy against PEL tumor progression in vivo.
Results
xCT is highly expressed on KSHV-infected PEL cell-lines
To first identify whether xCT is expressed on KSHV-
infected PEL cells, we tested its expression in 3 KSHV-
infected PEL cell-lines BC-1, BCP-1 and BCBL-1 (BC-1 was
also EBV+) using immunoblots. Our data demonstrated the
expression of xCT in all 3 KSHV-infected PEL cell-lines but
no significant difference at its expressional levels among
these cell-lines (Figure 1A). Next, using a monoclonal Ab
recognizing an extracellular domain of xCT in flow cytome-
try, we confirmed that xCT is highly expressed on the cell
surface of KSHV-infected PEL cell-lines including BCP-1and BCBL-1. Moreover, RNAi targeting xCT success-
fully reduced its expression on cell-surface and total
cellular levels (Figure 1B-C). To understand its rele-
vance in AIDS-related lymphoma, we also tested the
cell-surface expression of xCT on different lymphoma
cell-lines. We found that among 4 Burkitt’s lymphoma
cell lines, BL-41 and BJAB (both are KSHVneg/EBVneg)
highly expressed xCT, AKATA (KSHVneg/EBV+) inter-
mediately expressed xCT while RAMOS (KSHVneg/
EBVneg) was lack of xCT expression (Additional file 1:
Figure S1). In addition, one diffuse large cell lymphoma
(DLCL) cell line CRL2631 (KSHVneg/EBVneg) also inter-
mediately expressed xCT on cell-surface (Additional
file 1: Figure S1).
Targeting xCT induces KSHV-infected PEL cell death/
apoptosis in vitro
To investigate the role of xCT in PEL cell growth/survival,
we treated them with two well-known xCT specific inhibi-
tors [13], Monosodium glutamate (MSG) and Sulfasala-
zine (SASP). After 48-h treatment, both MSG and
SASP significantly reduced cell viability for BC-1, BCP-
1 and BCBL-1 in a dose-dependent manner by using
MTT assays (Figure 2A-B). Further experiments dem-
onstrated that MSG or SASP treatment increased pro-
apoptotic cleaved-caspase 3 and 9 expression, while not
changing xCT itself expression within BCP-1 and
BCBL-1 (Figure 2C). Flow cytometry analysis also indi-
cated that MSG or SASP treatment only slightly re-
duced xCT expression on the surface of these cells
(Additional file 1: Figure S2), implying that both drugs
mainly block the functions of xCT but not affecting its
expression or cellular location. By using Annexin-PI
staining, we confirmed that both MSG and SASP treat-
ment induced BCP-1and BCBL-1 cells undergoing apop-
tosis in a dose- and time-dependent manner (Figure 2D,
Additional file 1: Figure S3). To exclude MSG- or SASP-
induced cell apoptosis is due to non-specific “off-target”,
we used RNAi assays to directly silence xCT in PEL cells.
As shown in Figure 2E, “knock-down” xCT significantly
induced cell apoptosis for BCP-1 and BCBL-1, confirming
the role of xCT in PEL cell growth/survival. Additional
data indicated that inhibition of xCT by SASP also in-
duced significant apoptosis for BL-41 lymphoma cells
with highly expressed xCT, while had very slight effects
on RAMOS lymphoma cells with deficient xCT expres-
sion (Additional file 1: Figure S1 and S4).
Inhibition of xCT reduces intracellular glutathione (GSH)
but increasing reactive oxygen species (ROS) from
KSHV-infected PEL cells
As mentioned above, expression of xCT on the cell mem-
brane is essential for the uptake of cystine required for
intracellular GSH synthesis, which plays an important role
Figure 1 xCT is highly expressed on KSHV-infected PEL cells. (A) Immunoblots were performed to identify xCT expression for 3 KSHV-infected
PEL cell lines (BC-1, BCP-1 and BCBL-1). Expression of β-actin was assessed for loading controls. (B-C) PEL cells were transfected with negative control
siRNA (n-siRNA) or siRNA targeting xCT for 48 h. Cells were then incubated with a monoclonal Ab recognizing an extracellular domain of xCT, followed
by a secondary Ab conjugated to Alexa-647. PEL cell surface expression of xCT was then quantified by flow cytometry (B). The total xCT expression
was measured by immunoblots (C).
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Therefore, we sought to determine whether MSG or SASP
treatment affected intracellular GSH and ROS levels for
KSHV-infected PEL cells. By using a commercial GSH-
assay kit, we found that both drugs apparently reduced
intracellular GSH from BCP-1 and BCBL-1 cells, espe-
cially SASP (Figure 3). In contrast, impaired GSH synthe-
sis by these xCT inhibitors increased intracellular ROS
production within PEL cells (Figure 4A), shown by using a
ROS-specific dye, 5-(and-6)-chloromethyl-2′,7′-dichloro-
dihydrofluorescein diacetate, acetyl ester (CM-H2DCFDA)
[23]. Here we used one of NF-κB inhibitors, Bay11-7082
as a positive control, because published data have shown
blocking NF-κB pathway increasing ROS production and
inducing cell apoptosis from KSHV-infected PEL [23]. As
we know, ROS production requires the NADPH oxidase
complex, which contains various NADPH oxidases and
cytosolic components depending on the stimulus signals
and cell types [24,25]. Our further data demonstrated that
inhibition of xCT mainly upregulated the expression of
Rac1/p22phox/Nox1/Nox2 axis for ROS production, al-
though the elevated levels are subtle different between
BCP-1 and BCBL-1 cells, while very little impacts on
p47phox and Nox4 proteins (Figure 4B). In functionalvalidation, we confirmed that MSG and SASP treatment sig-
nificantly elevated the activities of NADPH oxidases within
BCP-1 and BCBL-1 (Figure 4C), using a luminescence-
based biochemical assay as described previously [26]. In
parallel, we found that RNAi directly silencing xCT also
increased intracellular ROS production from BCBL-1
cells potentially through activating the Rac1/ p22phox/
Nox1/Nox2 axis (Additional file 1: Figure S5). To block
ROS production, we next employed one of H₂O₂ scav-
engers, the antioxidant N-acetylcysteine (NAC). We found
that NAC treatment significantly reduced BCBL-1 cell
apoptosis induced by xCT inhibitors MSG and SASP
(Figure 4D), although which cannot completely prevent
the induced cell apoptosis implying that other ROS-
independent mechanisms are potentially involved.
Akt complex activities are reduced by xCT inihibitors
The Akt pathway and related molecules have been found
essential for maintaining growth/survival of KSHV-
infected PEL cells [7,27]. Blocking Akt complex activities
by a variety of compounds induced PEL cell apoptosis
and tumor progression in vitro and in vivo [9,28,29].
Here we found that both MSG and SASP treatment re-
duced the phosphorylation of Akt and downstream
Figure 2 (See legend on next page.)
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Figure 2 Targeting xCT induces apoptosis and death for KSHV-infected PEL cells. (A-B) KSHV-infected BC-1, BCP-1 and BCBL-1 cells were
incubated with xCT inhibitor either Monosodium glutamate (MSG), or Sulfasalazine (SASP) at the indicated concentrations for 48 h, then cell
viability was assessed by standard MTT assays. (C) BCP-1 or BCBL-1 were treated with MSG (20 mM), SASP (0.5 mM) or vehicle for 24 h, then
proteins expression were measured by immuoblots. (D-E) BCP-1 or BCBL-1 were incubated with MSG or SASP at the indicated concentrations
for 24 h (D), or transfected with negative control or xCT-siRNA for 48 h (E). Cell apoptosis was assessed using Annexin V-PI staining and flow
cytometry analysis. Error bars represent the S.E.M. for 3 independent experiments. * = p < 0.05; ** = p < 0.01.
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SASP also effectively repressed the phosphorylation of
P70S6 and S6, the two important downstream interme-
diates of Akt pathway [7]. We also looked at another
protein, X-linked inhibitor of apoptosis protein (XIAP),
a physiologic substrate of AKT that is stabilized to in-
hibit programmed cell death and has a direct effect on
caspase-3 and 9 [30]. Our data indicated that XIAP ex-
pression was greatly reduced in MSG- and SASP-
treated PEL cells when compared with vehicle-treated
cells (Figure 5). In parallel, RNAi directly silencing xCT
also effectively reduced the phosphorylation of Akt from
BCBL-1 cells (Additional file 1: Figure S5B). Taken to-
gether, these data demonstrate that the Akt pathway is in-
deed involved in the regulation of PEL growth/survival by
xCT.
Inhibition of xCT induces viral lytic gene expression from
KSHV-infected PEL cells
PEL tumor cells are usually latently infected by KSHV
with consistent expression of several viral latent proteins
and microRNAs [31]. Therefore, it is interested to know
whether inhibition of xCT has impacts on viral gene
profile within these cells. Notably, we found that both
MSG and SASP treatment dramatically induces viral
lytic gene expression, including lytic ‘switch” gene Rta
and vGpcr, vIL-6, K8.1, Orf57, while slightly increased la-
tent gene Lana expression within BCP-1 and BCBL-1Figure 3 xCT inhibition reduces intracellular GSH levels from KSHV-in
with either MSG or SASP at the indicated concentrations for 24 h, then intr
described in Methods, and normalized to GSH levels for the vehicle-incuba
* = p < 0.05; ** = p < 0.01.(Figure 6A-B). To confirm qRT-PCR results, we detected
one of viral lytic ptroteins, K8.1 expression using IFA
and immunoblots. As shown in Figure 6C-D, K8.1 ex-
pression was significantly increased in the cytoplasma of
MSG- or SASP-treated BCBL-1 cells, while only low-
level of basal expression was observed in vehicle-treated
cells. In parallel, RNAi directly silencing xCT also signifi-
cantly induced viral lytic gene expression such as Rta,
vGpcr and K8.1 from BCBL-1 cells (Additional file 1:
Figure S6). In addition, we found that inhibition of xCT
by MSG and SASP caused virion production from partial
BCBL-1 cells (especially MSG) when compared with val-
proic acid, a well-known KSHV lytic chemical inducer
(Figure 6E).
xCT inhibitor suppresses PEL tumor progression in vivo
As noted above, the xCT inhibitors MSG and SASP in-
duced significant cell-apoptosis for KSHV-infected PEL
in vitro. Unfortunately, MSG is a neurotoxin that pre-
cludes its use as a therapeutic agent [32]. In contrast,
SASP has been routinely used in the clinic to treat in-
flammatory bowel disease and rheumatoid arthritis [13],
induces cystine starvation and growth arrest in a variety
of cancer cells in vitro and in vivo [13,15,16,33,34]. How-
ever, to our knowledge its activity against virus-associated
tumors including PEL has not been explored. Therefore,
we sought to determine the activity of SASP against PEL
tumors in vivo utilizing an established xenograft modelfected PEL cells. (A-B) BCP-1 (A) and BCBL-1 (B) cells were incubated
acellular glutathione (GSH) was quantified using a commercial kit as
ted cells. Error bars represent the S.E.M. for 3 independent experiments.
Figure 4 xCT inhibition induces intracellular ROS levels through upregulation of NADPH oxidases activities from KSHV-infected PEL
cells. (A) BCP-1 and BCBL-1 were incubated with either MSG or SASP at the indicated concentrations for 24 h, then intracellular reactive oxygen
species (ROS) were quantified using the ROS-specific dye CM-H2DCFDA and flow cytometry, and normalized to ROS levels for the vehicle-incubated
cells. NF-κB inhibitor Bay11-7082 was used as a positive control. (B-C) BCP-1 and BCBL-1 were treated with either MSG (20 mM), SASP (0.5 mM) or
vehicle for 24 h, then proteins expression were measured by immuoblots. NADPH oxidases activities were measured as described in Methods. (D)
BCBL-1 were treated with either MSG (20 mM), SASP (0.5 mM) or vehicle in the presence or absence of the antioxidant N-acetylcysteine (NAC) 2.5 mM
for 48 h, then cell apoptosis was assessed using Annexin V-PI staining and flow cytometry analysis (** vs MSG group; ## vs SASP group). Error bars
represent the S.E.M. for 3 independent experiments. * = p < 0.05; **/## = p < 0.01.
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of immune compromised mice [9]. In this model, we
injected BCBL-1 cells into NOD/SCID mice and observed
clear PEL expansion within 3–4 weeks post-injection, in-
cluding time-dependent weight gain and increased ab-
dominal girth, as well as ascites accumulation and splenic
enlargement due to tumor infiltration at the time of nec-
ropsy [9]. In the current study, we administered SASP
(150 mg/kg) or vehicle i.p. within 24 hours of PEL cell in-
jection. SASP treatment dramatically suppressed PEL
tumor progression in vivo, including reduced weight/
tumor gain, ascites formation and splenic enlargement when
compared with the vehicle-treated mice (Figure 7A-C).
Using the ascites tumor cells collected and purified from
vehicle- or SASP-treated mice, we found that there weremuch higher apoptotic cell subpopulation in ascites
from SASP-treated mice than those from the vehicel-
treated group (Figure 7D). We also quantified viral gene
profile of ascites-derived PEL cell lysates from each
group. We found that PEL cells from SASP-treated mice
exhibited significantly increased expression of viral lytic
genes profiled (Rta, vGpcr, K8.1), while slightly increasing
the latent Lana transcripts (Figure 7E).
Discussion
As mentioned above, our published data demonstrated
that xCT is highly expressed in advanced KS tumor tis-
sues from patients and important for KSHV pathogen-
esis [21,22]. However, in another major KSHV-related
malignancy, PEL, it is unclear whether xCT is expressed
Figure 5 Targeting xCT blocks the Akt pathway and related
protein expression. (A-B) BCP-1 (A) and BCBL-1 (B) cells were
treated with either MSG (20 mM) or SASP (0.5 mM) for 24 h, then
protein expression were measured by immuoblots.
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study, we provide experimental evidence that xCT is
crucial for PEL cell growth/survival and tumor expan-
sion in vivo through the complex mechanisms involving
both host and viral factors (Figure 8). Our data also indi-
cate that targeting xCT alone or combination of chemo-
therapy may represent a promising strategy against PEL
in future.
xCT expression is differentially regulated during oxi-
dative stress through transcription factors binding to the
cis-acting “Antioxidant Response Element” (ARE) in its
promoter [35,36]. Transcription factors that bind to the
ARE include a positive regulator known as Nuclear fac-
tor erythroid 2-related factor-2 (Nrf-2) [36] and negative
regulators, including BACH-1 and c-Maf, which com-
petitively reduce Nrf-2 binding to the ARE thereby
repressing ARE-mediated gene expression [37,38]. We and
others have confirmed that at least one KSHV-microRNA,
miR-K12-11, can directly target BACH-1 to increase xCT
expression [21,39,40]. In addition, c-Maf can also be dir-
ectly targeted by several KSHV-microRNAs to promote
endothelial cell reprogramming [41]. Therefore, it is inter-
ested to understand whether these KSHV-microRNAs
expressed within PEL cells represent the major contributor
to xCT expression and its functions in future studies.
Our data indicate that induction of PEL apoptosis by
targeting xCT is potentially through repressing intracel-
lular GSH, increasing ROS and viral lytic gene expres-
sion. In accordance with this, Li et al. have reported that
depletion of GSH and upregulation of ROS strongly in-
duce KSHV reactivation and final cell death for KSHV-infected PEL in vitro [23]. The authors also demonstrate
that ROS is upregulated by NF-κB inhibition and is re-
quired for subsequent KSHV reactivation. However, we
do not observe apparent NF-κB inhibition in MSG- or
SASP-treated PEL cells when compared with vehicle-
treated control (data not shown), implying NF-κB signal-
ing is not responsible for disruption of redox balance by
targeting xCT. On the other hand, it has been reported
that ROS-induction by KSHV plays a causal role in KS
oncogenesis by promoting proliferation and angiogenesis
[42]. Furthermore, Rac1 is overexpressed in AIDS-KS le-
sions and in KSHV-infected mECK36 tumors, and the
antioxidant NAC was able to completely suppress Rac1-
induced tumor formation in RacCA transgenic mice
[43]. Interestingly, published literature indicates a close
association between ROS upregulation and Akt signaling
activation in a variety of cells [44-46]. In the contrary,
we have found here that Akt signaling is greatly im-
paired while ROS production increased in MSG- or
SASP-treated PEL cells. We assume the presence of
other compensatory mechanisms for ROS upregulation
when Akt signaling is repressed by inhibition of xCT, al-
though which requires further experimental validation.
In fact, xCT is involved in more cellular functions in-
cluding multidrug resistance for cancer cells. The xc
−
transporter can mediate cellular uptake of cystine to en-
hance biosynthesis of glutathione, which has a major role
in the protection of cells from drug-induced oxidative
stress by mediating detoxification of drugs and their extru-
sion via multidrug resistance proteins [17,18,47-50]. For in-
stance, glutathione induces a conformational change within
the multidrug resistance-associated protein-1 (MRP1) and
impairs its interaction with a drug and subsequent extru-
sion function [51]. In a pharmacogenomics approach,
Huang et al. reported that linking expression of xCT
with potency of 1,400 candidate anticancer drugs iden-
tified 39 showing positive correlations, and 296 with nega-
tive correlations [18]. Interestingly, we recently identify a
membrane-protein-complex including Emmprin (CD147),
LYVE-1 (a hyaluronan receptor) and BCRP (a drug-efflux
pump protein), responsible for multidrug resistance of
KSHV-infected PEL cells [52,53]. Therefore, future work
will focus on determining whether xCT is also involved in
this protein-complex to mediate multidrug resistance for
PEL. Finally, it is interested to identify more cellular genes
within PEL cells potentially regulated by xCT, through
analysis of the global gene profile changed due to inhib-
ition of xCT using “-omics” technologies.
Materials and methods
Cell culture and reagents
Body cavity-based lymphoma cells (BCBL-1, KSHV+/EBVneg)
and a Burkitt’s lymphoma cell line BL-41 (KSHVneg/
EBVneg) were kindly provided by Dr. Dean Kedes
Figure 6 Inhibition of xCT induces viral lytic gene expression from KSHV-infected PEL cells. (A-B) BCP-1 (A) and BCBL-1 (B) cells were
treated with either MSG (20 mM), SASP (0.5 mM) or vehicle for 24 h, then viral latent (Lana) and lytic gene (Rta, vGpcr, vIL-6, K8.1, Orf57) transcripts
were quantified using qRT-PCR. Error bars represent the S.E.M for three independent experiments. (C-D) BCBL-1 were treated as above, then the
expression of viral lytic protein K8.1 was detected by immunofluorescence and immunoblots. (E) BCBL-1 were treated by vehicle, MSG (20 mM),
SASP (0.5 mM) and valproic acid (1.5 mM as a positive control), respectively, for 48 h, then the virion production were collected as described in
Methods, followed by infection of HUVEC cells. Lana transcripts from each group were quantified by qRT-PCR. Error bars represent the S.E.M. for 3
independent experiments, ** = p < 0.01.
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medium (Gibco) with supplements as described previously
[9]. The Burkitt’s lymphoma cell line BJAB (KSHVneg/
EBVneg), RAMOS (KSHVneg/EBVneg), AKATA (KSHVneg/
EBV+) were kindly provided by Dr. Erik Flemington
(Tulane University) and cultured as described elsewhere [54].
PEL cell line BC-1 (KSHV+/EBV+), BC-3 (KSHV+/EBVneg),
and BCP-1 (KSHV+/EBVneg) cells were purchased from
American Type Culture Collection (ATCC) and main-
tained in complete RPMI 1640 medium (ATCC) supple-
mented with 20% FBS. A diffuse large cell lymphoma
(DLCL) cell line CRL2631 (KSHVneg/EBVneg) was pur-
chased from ATCC and maintained in complete RPMI
1640 medium (ATCC) supplemented with 10% FBS.
Primary human umbilical vein endothelial cells (HUVEC)were cultured as described previously [21]. KSHV infec-
tion was verified for all cell lines using immunofluores-
cence assays for detection of the KSHV latency-associated
nuclear antigen (LANA) [9]. All cells were cultured at
37°C in 5% CO2. All experiments were carried out using
cells harvested at low (<20) passages. Monosodium glu-
tamate (MSG), Sulfasalazine (SASP) and Bay11-7082 were
purchased from Sigma.
Cell viability assays
Cell viability was assessed using MTT assays for assess-
ment of proliferative capacity, and flow cytometry for
quantitative assessment of apoptosis. The standard MTT
assays were performed as described previously [9]. For
flow cytometry, the FITC-Annexin V/propidium iodide
Figure 7 xCT inhibitor SASP suppresses PEL progression in vivo. (A-C) NOD/SCID mice were injected intraperitoneally (i.p.) with 107 BCBL-1
cells. Beginning 24 h later, 150 mg/kg SASP or vehicle (n = 8 per group) were administered intraperitoneally (i.p.) once daily, 5 days per week, for
each of 2 independent experiments. Images of representative animals and their respective spleens, as well as ascites fluid volumes, were collected
at the conclusion of experiments on day 28 (A/C). Weights were recorded weekly (B). Error bars represent the S.E.M. for 2 independent experiments,
** = p < 0.01. (D) Apoptosis was quantified by flow cytometry for live PEL cells purified from ascites fractions as described in Methods. (E) RNA was
recovered from live PEL cells from ascites fractions from each of 4 mice representing vehicle- or drug-treated groups. qRT-PCR was used to quantify
viral transcripts representing latent (Lana) or lytic genes (Rta, vGpcr, K8.1). Data were normalized to samples representing vehicle-treated mice.
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used according to the manufacturer’s instructions.Immunoblotting
Cells were lysed in buffer containing 20 mM Tris
(pH 7.5), 150 mM NaCl, 1% NP40, 1 mM EDTA, 5 mM
NaF and 5 mM Na3VO4. Total cell lysates (30 μg) were re-
solved by 10% SDS–PAGE, transferred to nitrocellulose
membranes, and immunoblotted using 100–200 μg/mL
antibodies, including cleaved-caspase 3/9, p-Akt/t-Akt,
p-GSKα/t-GSKα, p-P70S6/t-P70S6, p-S6/t-S6, XIAP, Rac1
(cell signaling), Nox1 (Abcam), xCT, p22phox, p47phox,
Nox2, Nox4 (Santa Cruz), KSHV-K8.1 (ABI). For loading
controls, blots were reacted with antibodies detecting β-
Actin (Sigma). Immunoreactive bands were developedusing an enhanced chemiluminescence reaction (Perkin-
Elmer) and visualized by autoradiography.
Immunofluorescence Assays (IFA)
Cells were incubated in 1:1 methanol-acetone at −20°C
for fixation and permeabilization, then with a blocking
reagent (10% normal goat serum, 3% bovine serum albu-
min, and 1% glycine) for an additional 30 minutes. Cells
were then incubated for 1 h at 25°C with 1:2000 dilu-
tion of a mouse anti-K8.1 monoclonal antibody (ABI)
followed by 1:200 dilution of a goat anti-mouse second-
ary antibody conjugated to Texas Red (Invitrogen). For
identification of nuclei, cells were subsequently counter-
stained with 0.5 μg/mL 4′,6-diamidino-2-phenylindole
(DAPI; Sigma) in 180 mM Tris–HCl (pH 7.5). Cells were
washed once in 180 mM Tris–HCl for 15 minutes and
Figure 8 The model of mechanisms for inducing KSHV-infected
PEL cell apoptosis and death by targeting xCT.
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confocal microscope.RNA interference
For RNA interference assays, xCT ON-TARGET plus
SMART pool siRNA (Dharmacon), or negative control
siRNA, were delivered using the DharmaFECT transfec-
tion reagent according to the manufacturer’s instructions.
To confirm initial transfection efficiency for siRNA experi-
ments, PEL cells were transfected with green fluorescent
protein (GFP)-tagged siRNA, and GFP expression deter-
mined by flow cytometry 24 h later as described previously
[9]. Three independent transfections were performed for
each experiment, and all samples were analyzed in tripli-
cate for each transfection.qRT-PCR
Total RNA was isolated using the RNeasy Mini kit accord-
ing to the manufacturer’s instructions (QIAGEN). cDNA
was synthesized from equivalent total RNA using Super-
Script III First-Strand Synthesis SuperMix Kit (Invitrogen)
according to the manufacturer’s procedures. Primers
used for amplification of target genes are displayed in
Additional file 2: Table S1. Amplification was carried
out using an iCycler IQ Real-Time PCR Detection System,
and cycle threshold (Ct) values were tabulated in duplicate
for each gene of interest in each experiment. “No tem-
plate” (water) controls were used to ensure minimal back-
ground contamination. Using mean Ct values tabulated
for each gene, and paired Ct values for β-actin as an in-
ternal control, fold changes for experimental groups rela-
tive to assigned controls were calculated using automated
iQ5 2.0 software (Bio-rad).Measurement of virion production
BCBL-1 cells (10 mL) were treated by vehicle, MSG
(20 mM), SASP (0.5 mM) and valproic acid (1.5 mM as a
positive control), respectively, for 48 h, then followed by
centrifugation at 1200 rpm for 5 min and 3000 rpm for
20 min. The clear supernatants were collected followed by
ultracentrifugation at 30000 g for 2 h, and virion pellet
were resuspended at 100 μL of fresh medium. The
HUVEC cells were infected with these virion suspensions
as described previously [22] and followed by qRT-PCR
measurement of Lana transcripts mentioned above.
ROS measurement
Vehicle-, MSG- and SASP-treated PEL cells were loaded
with 10 μM of the ROS dye c-H2DCFDA (Invitrogen)
for 30 min at 37°C in Hanks’ Balanced Salt Solution
(HBSS) containing calcium and magnesium (HBSS/Ca/
Mg). Cells will be washed once with HBSS/Ca/Mg to re-
move dye, resuspended in HBSS/Ca/Mg and subjected
to flow cytometry analyses as described elsewhere [23].
To block ROS production, PEL cells were treated with
MSG, SASP or vehicle in the presence or absence of the
antioxidant N-acetylcysteine (NAC) 2.5 mM for 48 h,
then cell apoptosis was assessed as described above.
Flow cytometry
Cells were resuspended in staining buffer (3 BSA in 1×
PBS) for 20 minutes, then incubated on ice for 30 min
with 1:20 dilution of primary antibody xCT (Santa Cruz).
Following two subsequent wash steps, cells were incu-
bated for an additional 30 min with 1:200 dilution of sec-
ondary antibodies (Invitrogen) including Donkey anti-goat
IgG Alexa Fluor 647. Controls included cells incubated
with the secondary antibody only. Cells were resuspended
in 1× PBS and analyzed using a FACS Calibur 4-color flow
cytometer (BD) and FlowJo software (TreeStar) to quan-
tify cell surface localization of target proteins.
NADPH oxidase activities assays
The chemiluminescence-based NADPH oxidase activ-
ities assays were performed as described previously with
modifications [26]. After drug-treatment, cells were cen-
trifuged at 500 g for 10 min at 4°C. The cell pellet was
resuspended with 35 μL ice-cold lysis buffer and kept on
ice for 20 min. To a final 200 μl of HBSS/Ca/Mg buffer
containing NADPH (1 μM, Sigma) and lucigenin (20 μM,
Sigma), 5 μl of cell lysates was added to initiate the re-
action for 5 min at 37°C. Chemiluminescence was mea-
sured immediately using a Synergy HT microplate
reader (BioTek Instruments).
Intracellular GSH measurement
The intracellular GSH levels in vehicle-, MSG- and
SASP-treated PEL cells were quantified using the GSH-
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PEL xenograft model
BCBL-1 cells maintained at early passage number in cell
culture were washed twice in sterile-filtered PBS prior to
performance of trypan blue and flow cytometry assays
for verification of their viability. Aliquots of 107 viable
cells were diluted in 200 μL sterile PBS, and 6–8 week-
old male non-obese diabetic/severe-combined immuno-
deficient (NOD/SCID) mice (Jackson Laboratory, Taconic
Inc.) received intraperitoneal (i.p.) injections with a single
cell aliquot. SASP solutions were prepared at 20 mg/mL,
dissolved in 0.1 N NaOH in PBS at pH 7.2, and sterile-
filtered prior to in vivo administration. The SASP
(150 mg/kg body weight), or vehicle alone, was adminis-
tered using an insulin syringe for i.p. injection. Drug was
administered 24 h after BCBL-1 injection, once daily for
5 days/week. Two experiments, with 8 mice per group for
each experiment, were performed. The PEL expansion
in vivo was confirmed by testing the expression of cell-
surface markers including CD45, CD138, EMA and viral
protein LANA in nuclear within ascites tumor cells, using
IFA and flow cytometry as described in our previous
publications [9]. Weights were recorded weekly as a
surrogate measure of tumor progression, and ascites
fluid volumes were tabulated for individual mice at the
completion of each experiment. All protocols were ap-
proved by the Louisiana State University Health Science
Center Animal Care and Use Committee in accordance
with national guidelines.
Statistical analyses
Significance for differences between experimental and con-
trol groups was determined using the two-tailed Student’s
t-test (Excel 8.0).
Additional files
Additional file 1: Figure S1. xCT expression on cell-surface of
AIDS-related lymphoma. Figure S2. xCT expression on the surface of
vehicle-, MSG- or SASP-treated PEL cells. Figure S3. Targeting xCT
induces apoptosis for KSHV-infected PEL cells. Figure S4. Targeting xCT
induces apoptosis for AIDS-related lymphoma. Figure S5. Targeting
xCT by RNAi induces intracellular ROS levels through upregulation of
NADPH oxidases from KSHV-infected PEL cells. Figure S6. Targeting xCT by
RNAi induces viral lytic gene expression from KSHV-infected PEL cells.
Additional file 2: Table S1. Primer sequences for qRT-PCR in this study.
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